For healthcare professionals only

This promotional hub has been developed by Bayer plc and Bayer products are discussed. Bayer has fully funded the hub and is responsible for the content, logistics and selection of speakers. OmniaMed Communications has provided editorial, marketing and logistical support. © 2022 Bayer plc

Click here for Prescribing Information and Adverse Event Reporting for Kerendia (finerenone)

CKD and T2D:
Developments in the management of diabetic kidney disease (DKD)
Resource hub

Welcome to the CKD and T2D: Developments in the management of DKD resource hub for events and learning materials. Here you can find details of upcoming webinars that may be relevant to your clinical practice, as well as access a range of on-demand videos, podcasts and downloadable resources to support you in your ongoing education and development.

Throughout this website, the events and materials will focus on the role of Kerendia▼ (finerenone) in the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) in adults with type 2 diabetes. This website will be updated with additional materials on a regular basis, so do bookmark this site and revisit us. We hope you find these resources useful in your everyday clinical practice.

Click here for Prescribing Information and Adverse Event Reporting for Kerendia (finerenone)

Reporting adverse events and quality complaints

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.

If you want to report an adverse event or quality complaint, reports can be directed to:
Tel: 01182063500 or email: [email protected]

PP-KER-GB-0192 | September 2022

This promotional hub has been developed by Bayer plc and Bayer products are discussed. Bayer has fully funded the hub and is responsible for the content, logistics and selection of speakers.
OmniaMed Communications has provided editorial, marketing and logistical support.
© 2022 Bayer plc

This promotional hub has been developed by Bayer plc and Bayer products are discussed. Bayer has fully funded the hub and is responsible for the content,
logistics and selection of speakers.
OmniaMed Communications has provided editorial, marketing and logistical support.
© 2022 Bayer plc

Click here for Adverse Event reporting & Prescribing Information for Kerendia (finerenone)

CKD and T2D:
Developments in the management of Diabetic Kidney Disease (DKD)

Welcome to the CKD and T2D: Developments in the management of DKD resource hub for events and learning materials. Here you can find details of upcoming webinars that may be relevant to your clinical practice, as well as access to a range of on-demand videos, podcasts and downloadable resources to support you in your ongoing education and development.

Throughout this website, the events and materials will focus on the role of Kerendia▼ (finerenone) in the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) in adults with type 2 diabetes. This website will be updated with additional materials on a regular basis, so do bookmark this site and revisit us. We hope you find these resources useful in your everyday clinical practice.

Upcoming events

Filling in the gaps in the management of diabetic kidney disease

Wednesday 6 July at 13:00 or Thursday 7 July at 13:00 or 19:00

Video Resources

Play Video

Delaying the progression of chronic kidney disease in adults with type 2 diabetes: A new treatment option

Professor Philip Kalra and Dr Kieran McCafferty examine the burden of chronic kidney disease (CKD) in adults with type 2 diabetes (T2D), assess the clinical trial data for Kerendia▼ (finerenone) and its impact on the progression of of CKD associated with T2D, and outline prescribing considerations for Kerendia in people with CKD associated with T2D.

Click here for Prescribing Information and Adverse Event Reporting for Kerendia (finerenone)

Delaying the progression of chronic kidney disease in adults with type 2 diabetes: The FIDELIO-DKD trial

Dr Kieran McCafferty summarises the key learning points from the FIDELIO-DKD trial, which investigated the impact of Kerendia▼ (finerenone) on the progression of CKD associated with T2D in adults.

Click here for Prescribing Information and Adverse Event Reporting for Kerendia (finerenone)
Play Video

Speakers

Professor Philip Kalra

Consultant Nephrologist, Salford Royal NHS Foundation Trust, Professor, University of Manchester

Philip Kalra graduated from Cambridge University and is Professor of Nephrology in Salford and the University of Manchester, Consultant Nephrologist since 1995. He has major research focus on renovascular disease, cardiovascular disease in CKD, CKD progression and iron use in CKD. He is Director of Research in the Northern Care Alliance, the trust encompassing Salford Royal. He was Academic Vice President of the UK Renal Association 2016-19, Chair of the UK Kidney Research Consortium during this time and was Chair of the NIHR CRN Renal Disorders group from 2010 until 2018. He has been involved in the development of several large UK clinical trials in nephrology and cardiology, including the ASTRAL, PIVOTAL and IRONMAN trials, and he has played a role in amalgamating Cardio- Renal education and research within the UK.

Dr Kieran McCafferty

Consultant Nephrologist, Barts Health NHS Trust, Senior Lecturer, Queen Mary University London

Kieran McCafferty is a Consultant Nephrologist and Honorary Senior Lecturer at Barts Health NHS trust and Queen Mary University London. He has clinical and research interests in cardiorenal disease and diabetic kidney disease . He was the UK principal investigator for the the phase 3 FIDELIO-DKD study.

Podcasts

Episode 1

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,

Downloadable resources

FIDELIO-DKD info-graphic

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,

Click here to access Kerendia (finerenone) Prescribing Information.

Reporting adverse events and quality complaints

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.

If you want to report an adverse event or quality complaint, reports can be directed to:
Tel: 01182063500 or email: [email protected]

PP-KER-GB-0175 | July 2022

This promotional hub has been developed by Bayer plc and Bayer products are discussed. Bayer has fully funded the hub and is responsible for the content, logistics and selection of speakers.
OmniaMed Communications has provided editorial, marketing and logistical support.
© 2022 Bayer plc

You are leaving diabetesonthenet.com

We are not responsible for content hosted on third party websites.
You will be directed to: https://yellowcard.mhra.gov.uk

You are leaving this site.

You are now leaving http://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.

For healthcare professionals only

Are you a healthcare professional?

The information is intended for healthcare professionals only.
Please confirm below.